Cardiol Therapeutics Inc. (NASDAQ:CRDL) Forecasted to Post FY2024 Earnings of ($0.31) Per Share

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Analysts at Leede Jones Gab lifted their FY2024 earnings per share estimates for Cardiol Therapeutics in a report issued on Monday, March 25th. Leede Jones Gab analyst D. Loe now forecasts that the company will earn ($0.31) per share for the year, up from their previous forecast of ($0.32). Leede Jones Gab also issued estimates for Cardiol Therapeutics’ FY2026 earnings at ($0.27) EPS.

Cardiol Therapeutics Stock Down 1.1 %

Shares of CRDL opened at $1.80 on Thursday. Cardiol Therapeutics has a 12-month low of $0.45 and a 12-month high of $2.17. The stock’s fifty day simple moving average is $1.42 and its 200-day simple moving average is $1.07.

Hedge Funds Weigh In On Cardiol Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Advisor Group Holdings Inc. increased its holdings in shares of Cardiol Therapeutics by 2,240.7% in the first quarter. Advisor Group Holdings Inc. now owns 113,058 shares of the company’s stock worth $173,000 after acquiring an additional 108,228 shares in the last quarter. Vident Investment Advisory LLC increased its holdings in shares of Cardiol Therapeutics by 139.6% in the first quarter. Vident Investment Advisory LLC now owns 126,157 shares of the company’s stock worth $195,000 after acquiring an additional 73,512 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Cardiol Therapeutics by 66.2% in the first quarter. Royal Bank of Canada now owns 35,214 shares of the company’s stock worth $54,000 after acquiring an additional 14,020 shares in the last quarter. Tejara Capital Ltd bought a new stake in shares of Cardiol Therapeutics in the fourth quarter worth about $225,000. Finally, Jane Street Group LLC bought a new stake in shares of Cardiol Therapeutics in the fourth quarter worth about $32,000. Institutional investors and hedge funds own 12.49% of the company’s stock.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.